temorel TEMOZOLOMIDE

Introduction to temorel

Temorel is a medication primarily used in the treatment of certain brain tumors. It is available in tablet form and is specifically used for aggressive types of cancer affecting the brain, such as glioblastoma multiforme and anaplastic astrocytoma. Temorel is a crucial option in oncology for managing these conditions.

Composition of temorel

Temorel contains the active ingredient Temozolomide, which belongs to a class of drugs known as alkylating agents. These agents work by adding an alkyl group to the DNA of cancer cells, causing damage that prevents the cells from growing and dividing.

Uses of temorel

• Treatment of glioblastoma multiforme
• Treatment of anaplastic astrocytoma

Side effects of temorel

• Common side effects: nausea, vomiting, fatigue
• Serious side effects: severe bone marrow suppression, increased risk of infection

Precautions of temorel

Patients taking temorel should be aware that it can lower blood cell counts, increasing the risk of infections. It is not recommended for use during pregnancy due to potential harm to the unborn baby. Patients with severe bone marrow suppression should avoid using this medication.

How to Take temorel

Temorel is typically taken orally in tablet form. The usual starting dose for adults is 150 mg/m² once daily for five days in a 28-day cycle. It should be taken on an empty stomach, either one hour before or two hours after a meal. Always follow your doctor's advice for the correct dosage and administration.

Conclusion of temorel

Temorel, containing the active ingredient Temozolomide, is a vital medication in the therapeutic class of alkylating agents. It is primarily used to treat aggressive brain tumors such as glioblastoma multiforme and anaplastic astrocytoma. Manufactured by leading pharmaceutical companies, temorel plays a significant role in oncology. Patients should be aware of its side effects and precautions to ensure safe and effective use. Temorel remains a key option for managing specific brain cancers.